miRNA调节免疫检查点在肿瘤治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2018.01.011

Abstract

Abstract: One of the main mechanisms of tumorigenesis and development is silencing of the patient's immune response to cancer-specific antigens.The defect of cancer immune surveillance may occur at any stage of tumor progression.In the tumor microenvironment,the abnormal expression of the immune checkpoint molecules that have an activation or inhibition effect on T lymphocytes can cause immune tolerance or escape of tumor cells.Targeted immune checkpoint molecules such as PD-1(programmed cell death protein 1)and its ligand PD-L1,have been shown to be new directions for the treatment of many types of cancer.microRNAs(miRNAs)play an important role in tumor microenvironment.Studies have shown that miRNAs are highly expressed in some tumors and play an important role in immune response,especially in early regulation.Therefore,miRNAs may be ideal candidates for the regulation of immune checkpoints in cancer therapy.The abnormal expression of multiple miRNAs in cancer cells provides new opportunities for cancer therapy,but the exact function of these miRNAs and their interaction with immune checkpoints are still in the exploratory phase.This review summarizes the recent findings regarding the use of miRNAs as molecular regulators of immune checkpoints and their potential applications in the treatment of cancer in clinical practice.

Key words: miRNA, Immune checkpoints, Cancer, Immune therapy

CLC Number:

MIAO Suping, GUO Erliang, PEI Rong, JIANG Huanyu, MIAO Susheng. Research progress in miRNA regulatory immune checkpoint in cancer therapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 57-62.

References

1 Chen DS,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
2 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
3 Dong H,Strome SE,Salomao DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:A potential mechanism of immune evasion[J].Nat Med,2002,8(8):793-800.
4 Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J].J Exp Med,2000,192(7):1027-1034.
5 Zolkind P,Uppaluri R.Checkpoint immunotherapy in head and neck cancers.[J].Cancer Metastasis Rev,2017,36(3):475-489.
6 Sharma P,Allison JP.The future of immune checkpoint therapy[J].Science,2015,348(6230):56-61.
7 Egen JG,Kuhns MS,Allison JP.CTLA-4:new insights into its biological function and use in tumor immunotherapy[J].Nat Immunol,2002,3(7):611-618.
8 Zhang X,Schwartz JC,Guo X,et al.Structural and functional analysis of the costimulatory receptor programmed death-1[J].Immunity,2004,20(3):337-347.
9 Mcdermott DF,Atkins MB.PD-1 as a potential target in cancer therapy[J].Cancer Med,2013,2(5):662-673.
10 Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation.[J].Nat Immunol,2001,2(3):261-268.
11 Crispen PL,Sheinin Y,Roth TJ,et al.Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma[J].Clin Cancer Res,2008,14(16):5150-5157.
12 Yi KH,Chen L.Fine tuning the immune response through B7-H3 and B7-H4[J].Immunol Rev,2009,229(1):145-151.
13 Goldberg MV,Drake CG.LAG-3 in cancer immunotherapy[J].Curr Top Microbiol Immunol,2011,344(1):269-278.
14 Tang D,Lotze MT.Tumor immunity times out:TIM-3 and HMGB1[J].Nat Immunol,2012,13(9):808-810.
15 Orang AV,Safaralizadeh R,Kazemzadehbavili M.Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation[J].Int J Genomics,2014,2014:970607.
16 Ambros V,Lee RC.Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning[J].Methods Mol Biol,2004,265(265):131-158.
17 Botta C,Cucè M,Caracciolo D,et al.Immunomodulatory activity of microRNAs:potential implications for multiple myeloma treatment.[J].Curr Cancer Drug Targets,2017,17(9):819-838.
18 Eichmüller SB,Osen W,Mandelboim O,et al.Immune modulatory microRNAs involved in tumor attack and tumor immune escape.[J].J Natl Cancer Inst,2017,109(10)1.
19 Ji Y,Hocker JD,Gattinoni L.Enhancing adoptive T cell immunotherapy with microRNA therapeutics.[J].Semin Immunol,2016,28(1):45-53.
20 Kuninty PR,Schnittert J,Storm G,et al.microRNA targeting to modulate tumor microenvironment[J].Front Oncol,2016,6(1):3.
21 Guo Y,Wang AY.Novel immune check-point regulators in tolerance maintenance[J].Front Immunol,2015,6:421.
22 Bauman JE,Cohen E,Ferris RL,et al.Immunotherapy of head and neck cancer:Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting[J].Cancer,2017,123(7):1259-1271.
23 Schadendorf D,Hodi FS,Robert C,et al.Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma[J].J Clin Oncol,2015,33(17):1889-1894.
24 Eggermont AM,Chiarion-Sileni V,Grob JJ,et al.Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy[J].N Engl J Med,2016,375(19):1845-1855.
25 Robert C,Long GV,Brady B,et al.Nivolumab in previously untreated melanoma without BRAF mutation[J].N Engl J Med,2015,372(4):320-330.
26 Reck M,Rodríguezabreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.[J].N Engl J Med,2016,375(19):1823-1833.
27 Hugo W,Zaretsky JM,Sun L,et al.Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma[J].Cell,2016,165(1):35-44.
28 Zaretsky JM,Garcia-Diaz A,Shin DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma[J].N Engl J Med,2016,375(9):819-829.
29 Xu S,Tao Z,Hai B,et al.MiR-424(322)reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint[J].Nat Commun,2016,7:11406.
30 Liu X,Jiang L,Wang A,et al.microRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines[J].Cancer Lett,2009,286(2):217-222.
31 Yeh YM,Chuang CM,Chao KC,et al.microRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α[J].Int J Cancer,2013,133(4):867-878.
32 Wei J,Nduom E,Kong LY,et al.MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints[J].Neuro Oncol,2016,18(5):639-648.
33 Crawford A,Wherry EJ.The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses[J].Curr Opin Immunol,2009,21(2):179-186.
34 Schneider C,Setty M,Holmes AB,et al.microRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas[J].Proc Natl Acad Sci U S A,2014,111(22):8185-8190.
35 Xi W,Jinge L,Ke D,et al.Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia[J].Cell Signal,2015,27(3):443-452.
36 Cortez MA,Ivan C,Valdecanas D,et al.PDL1 regulation by p53 via miR-34[J].J Natl Cancer Inst,2015,108(1):303.
37 郝小军,王传卓,赵相轩,等.miR-34a对结肠癌细胞SW480增殖、迁移和侵袭能力的影响及机制探讨[J].实用肿瘤学杂志,2017,31(3):193-198.
38 Soussi T.p53 alterations in human cancer:more questions than answers[J].Oncogene,2007,26(15):2145-2156.
39 Chen L,Gibbons DL,Goswami S,et al.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression[J].Nat Commun,2014,5:5241.
40 Zhou J,Zhou Y,Yin B,et al.5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro[J].Oncol Rep,2010,23(1):121-128.
41 曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.
42 Pandya D,Mariani M,Mchugh M,et al.Herpes virus microRNA expression and significance in serous ovarian cancer[J].PLoS One,2014,9(12):e114750.
43 Pandya D,Mariani M,He S,et al.Epstein-Barr virus microRNA expression increases aggressiveness of solid malignancies[J].PLoS One,2015,10(9):e0136058.
44 Gong AY,Zhou R,Hu G,et al.MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes[J].J Immunol,2009,182(3):1325-1333.
45 Guo W,Tan W,Liu S,et al.MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma.[J].Tumour Biol,2015,36(11):9049-9057.
46 Elmén J,Lindow M,Schütz S,et al.LNA-mediated microRNA silencing in non-human primates[J].Nature,2008,452(7189):896-899.
47 Krutzfeldt J,Rajewsky N,Braich R,et al.Silencing of microRNAs in vivo with “antagomirs”[J].Nature,2005,438(7068):685-689.

[1]	SUN Lichao,YANG Jing,SUN Lixin,ZHANG Yuan,YANG Zhihua,RAN Yuliang. Identification of monoclonal antibodies against hepatoma stem cells by screening for hepatoma spheroid cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 193-199.
[2]	ZHANG Jiawen,YU Yan,ZHANG Wei,CAO Jingyan,LUO Wen,SHANG Lihua. Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 200-205.
[3]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[4]	QIN Wen,ZHAO Nannan,HAN Yonghuan,XU Yajun. Expression of ZNF436 in gastric cancer and its effect on the migration and invasion of gastric cancer cells by WNT/β-catenin [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 222-227.
[5]	LIU Zhiqiang,CHU Yanjie,LIU Jing,WANG Yanbo. Atractylenolide I regulates proliferation and invasion of lung cancer A549 cells through the TLR4/MyD88 pathway [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 228-232.
[6]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[7]	MENG Hai,DU Guanxiang,ZHU Liling,TANG Qiyun. The expression of WEE1 in gastric cancer and its influence on prognosis of patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 239-243.
[8]	LIU Jiayin,YAN Feihu,ZHANG Yanqiao. Genetic susceptibility of gastric cancer with single nucleotide polymorphisms(SNPs)of apoptotic genes - caspase-3 and caspase-7 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 250-255.
[9]	ZHANG Yanqiu,HAN Ameng,LI Jinwang,GU Tao,FU Zhanzhao,MAO Yu,ZHANG Zijian,YANG Zhen. The preliminary study on clinical application of CRT+ARC technique in patients with locally advanced lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 256-260.
[10]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[11]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[12]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[13]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[14]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[15]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.

Research progress in miRNA regulatory immune checkpoint in cancer therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments